Payment overview · 2025
General Payments
$743.27
39 reported records · 13 companies
Healthcare provider profile · identity verified
Barbara A Wright-Bruce, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOCIETY HILL, SC · NPI 1437123924
Verified facts
What the public records show
CMS Open Payments records show Barbara A Wright-Bruce, FNP received $743.27 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.04 | 23.0% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.82 | 18.8% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.26 | 12.6% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.08 | 8.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.72 | 6.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.08 | 6.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.39 | 5.4% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $30.08 | 4.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.43 | 4.0% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.47 | 3.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.79 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.86 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.25 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.27 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.82 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.96 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $93.26 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.31 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 303 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 75 |
| Montelukast Sodium | Montelukast Sodium | 250 | 73 |
| Potassium Chloride | Potassium Chloride | 227 | 64 |
| Famotidine | Famotidine | 219 | 60 |
| Chlorthalidone | Chlorthalidone | 207 | 70 |
| Simvastatin | Simvastatin | 188 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 170 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 49 |
| Mounjaro | Tirzepatide | 148 | 26 |
| Metformin Hcl | Metformin Hcl | 124 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 38 |
| Prednisone | Prednisone | 123 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 115 | 38 |
| Carvedilol | Carvedilol | 115 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 23 |
| Losartan Potassium | Losartan Potassium | 101 | 33 |
| Ozempic | Semaglutide | 101 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 21 |
| Lisinopril | Lisinopril | 99 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 28 |
| Furosemide | Furosemide | 89 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 89 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 85 | 24 |
| Mirtazapine | Mirtazapine | 83 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 23 |
| Lovastatin | Lovastatin | 76 | 20 |
| Meloxicam | Meloxicam | 76 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 36 |
| Jardiance | Empagliflozin | 71 | 22 |
| Metformin Hcl Er | Metformin Hcl | 67 | 19 |
| Trazodone Hcl | Trazodone Hcl | 64 | 17 |
| Clonidine Hcl | Clonidine Hcl | 62 | 16 |
| Fluconazole | Fluconazole | 62 | 30 |
| Ketoconazole | Ketoconazole | 62 | 26 |
| Spironolactone | Spironolactone | 62 | 20 |
| Eliquis | Apixaban | 60 | 14 |
| Omeprazole | Omeprazole | 58 | 21 |
| Valsartan | Valsartan | 57 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | 17 |
| Ibuprofen | Ibuprofen | 51 | 21 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 45 |
| Naproxen | Naproxen | 49 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Allopurinol | Allopurinol | 46 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Glimepiride | Glimepiride | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Telmisartan | Telmisartan | 43 | 16 |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Linzess | Linaclotide | 33 | 12 |
| Baclofen | Baclofen | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Topiramate | Topiramate | 25 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 19 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 12 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 13 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.27 · 39 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APRETUDE, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Kerendia, Korlym, LOKELMA, NUPLAZID, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VIVITROL, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error